Technology
Health
Biotechnology

Karyopharm Therapeutics

$5.42
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.01 (0.18%) Today
-$0.09 (-1.63%) After Hours

Why Robinhood?

You can buy or sell KPTI and other stocks, options, ETFs, and crypto commission-free!

About

Karyopharm Therapeutics Inc. Common Stock, also called Karyopharm Therapeutics, is a clinical-stage pharmaceutical company. Read More It is engaged in the discovery, development, and commercialization of drugs to treat cancer and other major diseases. The company intends to initiate a pivotal randomized Phase 3 study of selinexor in combination with bortezomib (Velcade) and low-dose dexamethasone (BOSTON) in patients with multiple myeloma. Karyopharm Therapeutics was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.

Employees
332
Headquarters
Newton, Massachusetts
Founded
2008
Market Cap
334.56M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
969.43K
High Today
$5.60
Low Today
$5.39
Open Price
$5.55
Volume
316.67K
52 Week High
$21.71
52 Week Low
$3.92

Collections

Technology
Health
Biotechnology
Therapy
Medical
Pharmaceutical
Cancer Prevention
Silver

News

Markets InsiderMar 14

Karyopharm Announces FDA Extension of Review Period for Selinexor New Drug Application

NEWTON, Mass., March 14, 2019 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) action date for the New Drug Application (NDA) for selinexor. The NDA, which is currently under Priority Review by the FDA, is seeking accelerated approval for selinexor in combination with dexamethasone for the treatment of patients with relapsed refractory ...

2,059
MarketBeatMar 5

Stock Price, News, & Analysis for Karyopharm Therapeutics

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B...

118
Guru FocusMar 1

Steven Cohen Ups Bet on Karyopharm Therapeutics

Billionaire investor Steven Cohen (Trades, Portfolio), who heads up hedge fund Point72 Asset Management, disclosed he upped his stake in Karyopharm Therapeutics Inc.

1,933

Earnings

-$0.96
-$0.84
-$0.72
-$0.60
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 9, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.